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AntibioticsAbstract Background: Although cancer patients are susceptible to infection, there is no evidence-
based published guideline on the appropriate use of antimicrobial treatment in this group of
patients.
Methods: We retrospectively collected medical records of all terminal cancer patients who died in
the oncology department over a 15-month period and were reviewed for the pattern of infection and
causes of antimicrobial use during the patients’ last admission of life.
Results: A total of 258 eligible patients were enrolled, there was an equal distribution of males and
females (M/F: 129/129), and the mean age was 60.5 years. 221 patients admitted with fever (85%),
22 patients (8.5%) got fever after hospitalization and 15 patients (5.8%) did not suffer from fever.
Among patients with fever, 46 patients (18.9%) had two infection episodes and 197 patients
(81.1%) had only one infection episode. The culture results revealed positive in 98 patients
(40%) with gram-negative organisms were the dominant organisms. The major infection sites were
the respiratory tract, urinary tract and wound. 114 patients (47%) received one antibiotic and 129
patients (53%) received more than one. The mean duration of hospitalization was signiﬁcantly
longer for infected patients than for uninfected patients (8.00 vs. 18.15 days, p= 0.0001). Outcome
of antibiotic use revealed 42 patients (17.3%) with symptoms improved 71 patients (29.2%) with
stationary symptoms and 130 patients (53.5%) revealed symptom deterioration.
Conclusions: Our study revealed that antibiotic therapy for terminal cancer patients should be on a
clear rationale. We need further study to clarify if there is survival effect with antibiotic use or not.
ª 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.D license.Introduction
Various factors either disease-related or therapy-induced make
cancer patients more susceptible to infections rather than nor-
mal persons. Most cancer patients have many symptoms that
148 A.A. Mohammed et al.not only cause discomfort, but also impact quality of life.
Although there are different symptoms depending on the type
of cancer, the most common symptoms include pain, fatigue,
dyspnea, nausea, vomiting, constipation, and altered mental
status [1–3]. Because one of the most important goals of
medical practitioners is to alleviate suffering and improve the
quality of life, many efforts and studies have focused on
symptom management and control in cancer patients [4].
Among those factors which cause discomfort, infection is
responsible for substantial patient distress and adverse
symptoms.
Infection in cancer patients has been widely reported, but
very few studies have focused on the infection and its manage-
ment in palliative care patients [5–9]. However, the extent of
beneﬁt and optimal antibiotic use in cancer patients who are
receiving palliative care, especially in their end-of-life period,
was still not well-documented, and certain controversies
remained unsettled [10].
We conducted a retrospective study in the King Abdullah
Medical City-Holy Capital; a Saudi Tertiary Care hospital to
investigate the pattern of infection and antibiotic use in those
special type of patients.Materials and methods
The current retrospective study included 258 terminal cancer
patients who died in the oncology department under palliative
care in the King Abdullah Medical City-Holy Capital
(KAMC-HC) during the period from October 2010 to Decem-
ber 2012. Eligibility criteria were;
 Pathological diagnosis of cancer.
 Evidence of advanced disease beyond cure.
 Death during hospitalization at KAMC-HC.
We recorded the demographic data of patients, including
sex, age, cancer diagnosis, and hospitalization durations at
the oncology ward. According to status on admission all
patients were assigned to one of three strata: infection-admit,
new-infection and infection-free. When infection was identi-
ﬁed, we recorded the date of infection and infection-related
information including the symptoms/signs associated with
infection, infection focus, bacteriological culture and the
pathogen results. When antibiotics were employed, we also
recorded the period of use. After the course of antibiotic use
was completed, we evaluated whether the initial infection-
related symptoms/signs had or had not improved.
Infection was deﬁned as the presence of symptoms or phys-
ical signs that were interpreted and assessed by the attending
physicians to have been caused by a microbial agent. We
considered infection developed after 72 h from admission as
nosocomial infections [11,12].Statistical methods
Data collected were analyzed using SPSS computer software
Continuous variables were summarized as mean and standard
deviation or median and range as appropriate. Categorical
data were presented as frequencies and percentages. Signiﬁ-
cance was deﬁned as a P-value of <0.05.Ethical consideration
Ethical approval to conduct the study was sought from the
IRB review committee before the commencement of the study.Results
Patient characteristics
During the study period, a total of 258 patients with advanced
cancer were enrolled into the palliative care service and
involved in our study. Among those patients, the male to
female sex distribution was 1:1 (129/129). The mean age was
60.5 (S.D. ± 15.6 ranging from 17 to 101).
221 patients (85.7%), admitted by fever, 22 patients (8.5%)
had got fever during the admission period; after 72 h from
admission and 15 patients (5.8%) were admitted and died
without fever or antibiotic. Among patients with fever, 46
patients (18.9%) had two infection episodes during the same
hospitalization period, and 197 patients (81.1%) had only
one infection episode. The common cancer types included
colorectal cancer, breast cancer, lung cancer and biliary system
(liver and biliary tract) Table 1.
Major symptoms and outcome after antibiotic use
For major symptoms represented by the patients and outcome;
check Table 2.
Infection characteristics
The major infection sites were the respiratory tract, urinary
tract and wound. Among the patient’s infective episodes; the
bacteriological culture results were positive in 98 patients
(40%) and negative in 145 patients (60%). The gram –negative
organisms were the dominant organisms (gram-negative vs.
gram-positive; 64 vs. 22) Table 3.
Causes of antibiotic use
All the patients with infective episodes in our study were
treated with antibiotics (100%) and continued till death. 114
patients (47%) received one antibiotic and 129 patients
(53%) received more than one. Ceftriaxone was the most com-
monly prescribed antibiotic, received by 81 patients (33.3%),
and followed by piperacillin/tazobactam received by 37
patients (15.2%) Table 4.
Duration of hospitalization
The median duration of hospitalization among the 258
patients who were enrolled into the palliative care service
and involved in our study was 14.5 days (ranging from 1 to
159 days), the other 15 non infected patients had a median
hospitalized duration of 5 days (ranging from 1 to 32 days).
For the 197 patients who had one infection episode, the
median hospitalized duration was 13 days (ranging from 1 to
159 days). Additionally, the 46 patients who had two episodes
had a median duration of hospitalization of 22 days (ranging
Table 1 Patient’s characteristics.
Numbers Percentage %
Sex
Male 129 50
Female 129 50
Total 258 50
Age
Mean 60.5
Standard deviation ±15.6
Range (minimum  maximum) 17–101
Status on admission
Fever on admission 221 85.7
*Get fever after admission 22 8.5
No fever at all 15 5.8
Total 258 100
Infection episodes
Once 197 81.1
Twice 46 18.9
Total 243 100
Primary cancer site
Colo- rectal 36 14
Breast 24 9.3
Biliary system 17 6.6
Sarcoma 9 3.5
Genitor-urinary 20 7.8
HCC** 20 7.8
Lung 22 8.5
Pancreas 17 6.6
H&N*** 9 3.5
CUP**** 12 4.7
Lymphomas and leukaemias 41 15.9
Stomach 9 305
Others 22 8.2
Total 258 100
* After 72 h from admission.
** Hepatocellular carcinoma.
*** Head and neck.
**** Cancer of unknown primary.
Table 2 Major symptoms and outcome after antibiotic use.
Major symptoms Frequency (TN* 243) Improvement
Number (%) Number (%)
Pain 155 (63.8) 31 12.8
Dyspnea 142 (58.4) 9 3.7
Delirium 77 (31.7) 0 0
Anxiety 48 (19.8) 0 0
Weakness 100 (41) 2 0.8
Total out come
Improved 42 17.3
Static 71 29.2
Deteriorated 130 53.5
* TN; total number of patients.
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with infection, their median duration of hospitalization was
14 days (ranging 1–107 days), and for the 22 patients who suf-
fered new infection during the admission period, their median
duration of hospitalization was 23.5 days (ranging from 155
days 4–159 days). The differences seen in hospitalized daysbetween infected and non-infected patients and between who
got fever twice and once were highly signiﬁcant (p< 0.001,
0.001 respectively) Table 5.Discussion
Palliative care is specialized medical care for people with
serious illnesses. It is focused on providing patients with relief
from the symptoms, pain and stress of a serious illness –– what-
ever the prognosis. The goal is to improve quality of life for
both the patient and the family as they are the central system
for care. End-of-life care provides physical, mental, and emo-
tional comfort to people who are living with and dying of
advanced illness [13]. The use of antimicrobials controlled
symptoms in the majority of the urinary tract infections, but
were less effective in controlling symptoms in the other sites
of infection [14].
Terminal cancer patients are highly susceptible to infections
due to a variety of causes such as concurrent debilities, asthe-
nia, decreased level of consciousness, immobility, deteriorated
nutritional and immune status when patients were close to end
of life.
In our study, in non neutropenic terminally ill cancer
patients, the total infection rate was 243 patients (94.2%);
221 patients (85.7%) admitted with infection and 22 patients
(8.5%) had got fever during the last admission period prior
to death with 46 patients (18.9%) having two infection epi-
sodes. This result is higher than that recorded in other studies
ranging from 63% to 87% [15–17]. This difference may be
explained by the variation in populations, study areas, care
facilities and the deﬁnition of infection.
The most frequent site of infection in our patients was
respiratory (48.6%), followed by urinary tract (12.3%) and
wound (4.1%). This results is corresponding to the study done
by Lam at 2005 [18], but different from the studies of Vitetta et
al. [19] Homsi et al.,[20] and Pereira et al. [21].
Although there are many clinical studies [22–24] that have
examined the safety and feasibility of oral antibiotics, still
the parenteral route is the main used one. In our study; among
the patients who received antibiotics, 98 patients (40%)
received antibiotics based on cultures and sensitivity and
87.2% of them used antibiotics through the parenteral route,
which can be explained by many factors such as poor general
condition of our patients which may affect on the swallowing,
the severity of infection and the physician’s own decision.
As we saw in our study; all patients with infective episodes
received antibiotics, which reﬂect the high prevalence of their
usages. We believe that the antibiotic use in patients under pal-
liative care even in their end of life days is fairly common prac-
tice. This can be explained by many reasons; ﬁrstly, many
patients were cared by medical oncologists with less experience
in palliative care so they chose aggressive treatment rather
than observation or symptom control. Second, still the patients
and their families prefer aggressive treatment by antibiotics
even with expected minimal out come. Third, many physicians
considered the use of antibiotic with the potential to postpone
the patient death. Fourth, the concept of antibiotic usage as a
part of usual care may give some symbolic comfort for patients
and their care givers. Lastly, in our center, before accepting
any case under palliative care, we routinely meet patients
and their family to explain the positive concept of palliative
Table 3 Infection characteristics.
Major sites of infection Frequency total number (243) Percentage %
Respiratory tract 118 48.6
Urinary tract 30 12.3
Wound 10 4.1
Bacteriological results
Positive cultures 98 40
Negative cultures 145 60
Classiﬁcation of organisms
Gram ve 64 26
Gram +ve 22 9
Mixed 12 4.9
Total number 98 100
Table 4 Pattern of antibiotic use.
Frequency total number (243) Percentage %
Antibiotic utilization pattern
Empirical 145 60
Based on culture and sensitivity 98 40
Administration route
Parenteral 212 87.2
Enteral 16 6.6
Both 15 6.2
Patients on antibiotics
One 114 47
More than one 129 53
Table 5 Infection and duration of hospitalization.
Variable Number (patient) median Range (days) (minimum maximum) p-Value
Total 258 14.5 158 (1–159)
Infection
No 15 5 31 (1–32)
Yes 243
Once 197 13 158 (1–159) 0.001
Twice 46 22 88 (2–90)
Admitted with infection 221 14 106 (1–107)
Get infection while admission 22 23.5 155 (4–159) p< 0.001
P-value < 0.05
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when we start and end antibiotic administration.
The use of antibiotics on terminal cancer patients at the end
of life for symptomatic improvement is still questionable; few
studies support the use of it [25–27], while many studies are
considered futile [19,28–32].
In the prospective report by Vitetta et al. [19], 37 patients
with 42 separate infection events were noted from 102
consecutive admitted terminal patients in a hospice ward and
after antibiotics were administered, the extent of symptom
control approached at least 40%. This study suggested that
appropriate antibiotic use as infection therapy provided bene-
ﬁts for symptom control in terminal cancer patients. On the
contrary, in reports by Oh et al. [21], antibiotics were usedon 119 patients among a total of 141 admitted terminal cancer
patients. In that study, only 15.1% of the patients had infec-
tious symptom improvement and more than half (55.4%) did
not have any beneﬁt what so ever. In our study; after antibiotic
use, 42 patients (17.3%) had symptom improvement, 71
patients (29.2%) had stationary symptoms and 130 patients
revealed symptom deterioration. The duration of hospitaliza-
tion was more prolonged in patients with infection in compar-
ison to patients without infection, especially for those who had
got infection during the hospitalization period and for whom
suffered from more than one episode.
The symptomatic treatment in advanced cancer patients at
end of life in the form of pain, fever and dyspnea with opioids
and antipyretics remain effective means but the prolonged life
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[33–35].
Limitation
There are two main limitations to our study, ﬁrstly; the hetero-
geneity of the sample as regards cancer diagnosis (hematology
vs. solid tumors). The second limitation was the retrospective
nature of the study which depends totally on medical documen-
tation of diagnosis, symptom severity and their response, and
other outcome measures. Also the variation in the choice of
antibiotic even within the same site of infection among different
physicians.Conclusions
The use of antibiotics in patients with advanced cancer near
their end of life is a common practice in our center. We must
know that antibiotics are not safe medications and had a long
list of potential adverse effects with increasing risk of antimi-
crobial resistance besides the signiﬁcant cost. So we need fur-
ther prospective studies to identify several factors such as the
origins of infection, performance status, and laboratory data
are that necessary to help in create guidelines or protocols to
effectively choose the most suitable patients and appropriate
antibiotic therapies.Conﬂict of interest
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